Dyadic H1 Revenue Up 52% But Losses Widen; $2.9M Share Sale to Fund Operations
DYAI is trading near its 52-week low of $0.655 (8.5% above the low).
Summary
Dyadic's H1 revenue rose 52% on grant funding, but Q2 revenue was flat year-over-year and net loss widened on higher grant and admin costs. The company warns it needs new financing, and has agreed to sell 3.625 million shares at $0.795 plus warrants to raise about $2.9 million, closing around August 14. This follows the going concern warning in the Q2 10-Q filed August 12, where cash reserves dropped to $4.8 million. The C1 platform shows progress on RSV, malaria, and Bundibugyo antigens, but the immediate focus is survival financing. The offering is priced near the current market price of $0.71, indicating modest dilution but also demand at these levels.
At the time of this announcement, DYAI was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.2M. The 52-week trading range was $0.65 to $1.60. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.